{"id":827404,"date":"2025-03-19T07:47:55","date_gmt":"2025-03-19T11:47:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-showcase-research-demonstrating-treatment-benefits-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-and-epidiolex-cannabidiol-at-americ\/"},"modified":"2025-03-19T07:47:55","modified_gmt":"2025-03-19T11:47:55","slug":"jazz-pharmaceuticals-to-showcase-research-demonstrating-treatment-benefits-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-and-epidiolex-cannabidiol-at-americ","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-showcase-research-demonstrating-treatment-benefits-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-and-epidiolex-cannabidiol-at-americ\/","title":{"rendered":"Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex\u00ae (cannabidiol) at American Academy of Neurology Annual Meeting"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic\u00a0hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia by Evaluating Low-Sodium Oxybate Treatment) study<\/i>\n <\/p>\n

\n Novel analysis of real-world\u00a0Epidiolex treatment patterns underscore importance of dose optimization for improved patient persistence<\/i>\n <\/p>\n

\n For U.S. media and investors only<\/i>\n <\/p>\n

\n
\n DUBLIN<\/span>
\n <\/span>, March 19, 2025<\/span><\/span> \/PRNewswire\/ — Jazz Pharmaceuticals plc\u00a0(Nasdaq: JAZZ)\u00a0today\u00a0announced that seven abstracts from across its neuroscience portfolio will be featured\u00a0at\u00a0the\u00a077th<\/sup> Annual\u00a0American Academy\u00a0of\u00a0Neurology\u00a0Meeting (AAN) being held April 5-9, 2025<\/span>, in San Diego<\/span>.<\/p>\n

Data presented at the meeting includes an updated presentation of top-line results of the open-label, single-arm, Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, evaluating the effectiveness and safety of low-sodium oxybate, Xywav\u00ae<\/sup> (calcium, magnesium, potassium, and sodium oxybates) oral solution, on key sleep outcomes and daytime symptoms, including excessive daytime sleepiness (EDS), in adults with narcolepsy or idiopathic hypersomnia (IH). Notably, the results from DUET demonstrated statistically significant improvements from baseline to end of treatment in Epworth Sleepiness Scale (ESS) scores, reduced sleep stage shifts, increased deep sleep and reduced number of awakenings among adults with narcolepsy treated with Xywav<\/i>. In adults with IH, Xywav <\/i>treatment also showed improvements in ESS and Idiopathic Hypersomnia Severity Scale scores. Further, new patient-reported data from DUET demonstrated the association of Xywav<\/i> treatment with improvements in daytime symptoms and functional impacts, including cognitive complaints, among adults with narcolepsy or IH. Xywav<\/i> is indicated for the treatment of EDS or cataplexy in patients 7 years of age and older with narcolepsy and for adults with idiopathic hypersomnia.<\/p>\n

“This year’s presentations at the AAN Annual Meeting reinforce our ongoing commitment to addressing debilitating neurological disorders, with limited or no treatment options including narcolepsy, idiopathic hypersomnia and epilepsy,” said Sarah Akerman<\/span>, MD, head of neuroscience global medical and scientific affairs of Jazz Pharmaceuticals. “We continually strive to expand our understanding, research and capabilities in neuroscience through ongoing data generation for Xywav<\/i> and Epidiolex<\/i> to ensure patients’ lived experiences and needs are reflected holistically. By listening to our patients, their care teams and leading industry experts, we aim to better address the unmet needs of those living with these difficult-to-treat conditions and ultimately help redefine possibilities for their lives.”<\/p>\n

Highlights at the 2025 AAN Annual Meeting\u00a0include:<\/p>\n